Compare ICCM & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICCM | PDSB |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.5M | 46.0M |
| IPO Year | N/A | N/A |
| Metric | ICCM | PDSB |
|---|---|---|
| Price | $0.64 | $0.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.50 | ★ $9.00 |
| AVG Volume (30 Days) | 375.3K | ★ 645.4K |
| Earning Date | 11-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,975,000.00 | N/A |
| Revenue This Year | $13.67 | N/A |
| Revenue Next Year | $38.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.59 | $0.70 |
| 52 Week High | $1.66 | $2.20 |
| Indicator | ICCM | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 35.36 | 52.42 |
| Support Level | $0.67 | $0.83 |
| Resistance Level | $0.72 | $1.13 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.53 | 51.73 |
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.